Author Details

Болотина, Лариса Владимировна

Issue Section Title File
Vol 15, No 3 (2013) Articles Gefitinib – terapiya vybora 1-y linii nemelkokletochnogo raka legkogo u bol'nykh s nalichiem mutatsiy v gene EGFR
Vol 21, No 2 (2019) Articles Unresectable hepatocellular carcinoma: new opportunities and prospects for therapy PDF
(Rus)
Vol 21, No 2 (2019) Articles The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience PDF
(Rus)
Vol 21, No 1 (2019) Articles Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Differentiated thyroid cancer PDF
(Rus)
Vol 23, No 1 (2021) CLINICAL ONCOLOGY Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice PDF
(Rus) PDF
(Eng)
Vol 23, No 2 (2021) CLINICAL ONCOLOGY Prostate cancer PDF
(Rus)
Vol 23, No 4 (2021) CLINICAL ONCOLOGY Gastric cancer: Russian clinical guidelines PDF
(Rus)
Vol 25, No 3 (2023) CLINICAL ONCOLOGY Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors” PDF
(Rus)
Vol 24, No 4 (2022) CLINICAL ONCOLOGY Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study PDF
(Rus)
Vol 26, No 1 (2024) Articles Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia PDF
(Rus)
Vol 26, No 1 (2024) Articles Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study PDF
(Rus)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies